[{"Assets_0_Q2_USD":1081486000.0,"CIK":"1743881","CommonStockSharesConverted_0_Q2_shares":152894108.0,"CommonStockSharesOutstanding_0_Q2_shares":149614740.0,"Country":"United States","EarningsPerShareBasic_1_Q2_USD":-0.66,"EarningsPerShareBasic_2_Q2_USD":-1.82,"Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","Market Cap":"1594164456.0","NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-242478000.0,"NetIncomeLossConverted_1_Q2_USD":-96348000.0,"NetIncomeLossConverted_2_Q2_USD":-259427000.0,"OfficialName":"BridgeBio Pharma Inc. Common Stock","RevenuesConverted_1_Q2_USD":54024000.0,"RevenuesConverted_2_Q2_USD":54486000.0,"SP500":"nan","Sector":"Health Care","StockholdersEquityConverted_0_Q2_USD":-457490000.0,"StockholdersEquity_0_Q2_USD":-464294000.0,"Ticker":"BBIO","filed":"20210805","footnote":"nan","form":"10-Q","fp":"Q2","fy":"2021.0","name":"BRIDGEBIO PHARMA, INC.","period":"20210630","qtrs":"0","uom":"USD"}]